[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MX2013010571A - Ensayo de diagnostico de anticuerpo. - Google Patents

Ensayo de diagnostico de anticuerpo.

Info

Publication number
MX2013010571A
MX2013010571A MX2013010571A MX2013010571A MX2013010571A MX 2013010571 A MX2013010571 A MX 2013010571A MX 2013010571 A MX2013010571 A MX 2013010571A MX 2013010571 A MX2013010571 A MX 2013010571A MX 2013010571 A MX2013010571 A MX 2013010571A
Authority
MX
Mexico
Prior art keywords
antibody assay
diagnostic antibody
diagnostic
amyloidosis
diagnosis
Prior art date
Application number
MX2013010571A
Other languages
English (en)
Other versions
MX343873B (es
Inventor
Martin Kleinschmidt
Stephan Schilling
Jens-Ulrich Rahfeld
Hans-Ulrich Demuth
Kristin Ebermann
Original Assignee
Probiodrug Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Probiodrug Ag filed Critical Probiodrug Ag
Publication of MX2013010571A publication Critical patent/MX2013010571A/es
Publication of MX343873B publication Critical patent/MX343873B/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención pertenece a ensayos de diagnóstico novedosos para el diagnóstico de amiloidosis, en particular enfermedad de Alzheimer, y aspectos relacionados. En particular, se proporcionan anticuerpos monoclonales y un ensayo de anticuerpo.
MX2013010571A 2011-03-16 2012-03-16 Ensayo de diagnostico de anticuerpo. MX343873B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161453449P 2011-03-16 2011-03-16
PCT/EP2012/054629 WO2012123562A1 (en) 2011-03-16 2012-03-16 Diagnostic antibody assay

Publications (2)

Publication Number Publication Date
MX2013010571A true MX2013010571A (es) 2013-12-02
MX343873B MX343873B (es) 2016-11-25

Family

ID=45833428

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013010571A MX343873B (es) 2011-03-16 2012-03-16 Ensayo de diagnostico de anticuerpo.

Country Status (15)

Country Link
US (2) US8809508B2 (es)
EP (1) EP2686346B1 (es)
JP (1) JP6220675B2 (es)
KR (1) KR102020072B1 (es)
CN (1) CN103459421B (es)
AU (1) AU2012228236B2 (es)
BR (1) BR112013023211B1 (es)
CA (1) CA2828433C (es)
DK (1) DK2686346T3 (es)
EA (1) EA032054B1 (es)
IL (1) IL227847A0 (es)
MX (1) MX343873B (es)
SG (1) SG192805A1 (es)
WO (1) WO2012123562A1 (es)
ZA (1) ZA201305946B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2904465C (en) 2013-03-15 2021-07-13 Probiodrug Ag Inhibitors of glutaminyl cyclase
EP3234611A1 (en) 2014-12-19 2017-10-25 Probiodrug AG Novel method for the detection of pglu-abeta peptides
WO2016137947A1 (en) * 2015-02-24 2016-09-01 Rpeptide, Llc Anti-amyloid-beta antibodies
EA038120B1 (ru) * 2015-07-16 2021-07-08 Пробайодраг Аг Гуманизированные антитела к пироглутаматному варианту бета-амилоида
CN114585883A (zh) * 2019-10-01 2022-06-03 瑞普利金公司 流体中蛋白质浓度的测定

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
DE60031792T2 (de) * 1999-12-08 2007-02-22 Intellect Neurosciences, Inc. Schimärische amyloid-beta peptide
US7117096B2 (en) * 2001-04-17 2006-10-03 Abmaxis, Inc. Structure-based selection and affinity maturation of antibody library
WO2004013172A2 (en) 2002-07-24 2004-02-12 Innogenetics N.V. Fragments of beta-amyloid as targets for vaccination against alzheimer disease
WO2004029629A1 (en) 2002-09-27 2004-04-08 Janssen Pharmaceutica N.V. N-11 truncated amyloid-beta nomoclonal antibodies, compositions, methods and uses
CA2554809C (en) 2004-02-05 2014-04-29 Probiodrug Ag Novel n-alkyl thiourea- and thioamide-substituted imidazolyl inhibitors of glutaminyl cyclase
ES2259270B1 (es) 2005-03-09 2007-11-01 Consejo Superior De Investigaciones Cientificas Metodo de diagnostico in vitro de la enfermedad de alzheimer mediante un anticuerpo monoclonal.
EP2043687A4 (en) 2006-06-29 2010-03-17 Centocor Ortho Biotech Inc ANTI-AMYLOID ANTIBODIES, COMPOSITIONS, METHODS AND USES
US7741354B2 (en) 2006-11-09 2010-06-22 Probiodrug Ag Inhibitors of glutaminyl cyclase
EP2089383B1 (en) 2006-11-09 2015-09-16 Probiodrug AG 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases
DK2091945T3 (da) 2006-11-09 2014-04-22 Probiodrug Ag Nye inhibitorer af glutaminylcyclase
JP5523107B2 (ja) 2006-11-30 2014-06-18 プロビオドルグ エージー グルタミニルシクラーゼの新規阻害剤
WO2008110523A1 (en) 2007-03-09 2008-09-18 Probiodrug Ag Imidazo [1,5-a] pyridine derivatives as inhibitors of glutaminyl cyclase
DK2160380T3 (da) 2007-04-18 2014-06-30 Probiodrug Ag Cyano-guanidin derivater som glutaminyl cyclase inhibitorer
WO2008128986A1 (en) 2007-04-18 2008-10-30 Probiodrug Ag Urea derivatives as glutaminyl cyclase inhibitors
WO2008128981A1 (en) 2007-04-18 2008-10-30 Probiodrug Ag Nitrovinyl-diamine derivatives as glutaminyl cyclase inhibitors
WO2008128985A1 (en) 2007-04-18 2008-10-30 Probiodrug Ag Thiourea derivatives as glutaminyl cyclase inhibitors
WO2008128982A1 (en) 2007-04-18 2008-10-30 Probiodrug Ag Thioxoquinazolinone derivatives as glutaminyl cyclase inhibitors
WO2008128984A1 (en) 2007-04-20 2008-10-30 Probiodrug Ag Aminopyrimidine derivatives as glutaminyl cyclase inhibitors
EA201070479A1 (ru) * 2007-10-15 2010-12-30 Сентокор Орто Байотек Инк. Человеческие антиамилоидные антитела, композиции, способы и их применение
AT506820B1 (de) * 2008-06-12 2011-07-15 Affiris Forschungs Und Entwicklungs Gmbh Vakzine gegen alzheimer-krankheit
KR101706789B1 (ko) * 2008-07-21 2017-02-14 프로비오드룩 아게 진단용 항체 검사법
WO2010128139A1 (en) * 2009-05-08 2010-11-11 Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin Biomarkers and methods for diagnosing alzheimer's disease and/ or mild cognitive impairment
CA2765602C (en) * 2009-06-29 2021-05-25 Bioarctic Neuroscience Ab N-terminal truncated protofibrils/oligomers for use in therapeutic and diagnostic methods for alzheimer's disease and related disorders

Also Published As

Publication number Publication date
SG192805A1 (en) 2013-09-30
AU2012228236B2 (en) 2016-10-27
AU2012228236A1 (en) 2013-10-03
CA2828433A1 (en) 2012-09-20
NZ614217A (en) 2015-12-24
KR20140006019A (ko) 2014-01-15
US20120237529A1 (en) 2012-09-20
ZA201305946B (en) 2014-10-29
CA2828433C (en) 2020-08-04
EP2686346B1 (en) 2016-12-14
EA032054B1 (ru) 2019-04-30
BR112013023211A2 (pt) 2016-11-22
EA201301029A1 (ru) 2014-05-30
US20140255414A1 (en) 2014-09-11
BR112013023211B1 (pt) 2022-11-08
CN103459421A (zh) 2013-12-18
EP2686346A1 (en) 2014-01-22
WO2012123562A1 (en) 2012-09-20
US8809508B2 (en) 2014-08-19
US9657089B2 (en) 2017-05-23
KR102020072B1 (ko) 2019-11-04
JP2014509860A (ja) 2014-04-24
CN103459421B (zh) 2017-07-14
DK2686346T3 (en) 2017-03-27
MX343873B (es) 2016-11-25
JP6220675B2 (ja) 2017-11-01
IL227847A0 (en) 2013-09-30

Similar Documents

Publication Publication Date Title
WO2010009987A3 (en) Diagnostic antibody assay
PH12021550083A1 (en) Human anti-tau antibodies
CY1122278T1 (el) Αντι il-36r αντισωματα
AR092818A1 (es) Anticuerpo tau humanizado
PH12015500125A1 (en) Anti-jagged 1/jagged 2 cross-reactive antibodies, activatable anti-jagged antibodies and methods of use thereof
BR112014005644A2 (pt) anticorpo anti-alfabetatcr
AU2018256498A1 (en) Antibodies to amyloid beta
TN2014000120A1 (en) Cd27l antigen binding proteins
CO6710903A2 (es) Un anticuerpo que reconoce y se une específicamente con un fosfo-epítope en la proteína tau de mamífero o en uno de sus fragmentos y una composición comprendiendo el mismo
MA34091B1 (fr) Anticorps anti-cd40
MX345092B (es) Anticuerpos anti-tau humanos,.
EA030777B9 (ru) Анти-альфа-синуклеинсвязывающие молекулы
EA201171388A1 (ru) Гуманизированные антитела, специфичные к протофибриллярной форме бета-амилоидного пептида
SG178886A1 (en) Humanized anti-cdcp1 antibodies
MX2015003150A (es) Anticuerpos específicos de polipeptido amiloide de islote humano (hiapp) y sus usos.
ATE553778T1 (de) Für humanes hepcidin spezifische antikörper
WO2008136774A8 (en) Antibodies binding to an intracellular prl-1 or prl-3 polypeptide
MX2013010571A (es) Ensayo de diagnostico de anticuerpo.
PH12013500432A1 (en) Anti-vegfr-3 antibody compositions
GB0706558D0 (en) Diagnostic assay
WO2012144784A3 (ko) 인간 간-카르복실에스터라제 １을 특이적으로 인식하는 단일클론 항체, 상기 항체를 생산하는 하이브리도마 세포주 및 이의 용도
AR124605A2 (es) Anticuerpos anti-il-36r
TN2013000068A1 (en) Anti-vegfr-3 antibody compositions
TH133365A (th) แอนติ-N3pGlu อะมัยลอยด์ เบต้าเพปไทด์ แอนติบอดี และการใช้ของมัน
FR2980579B3 (fr) Procede et kit pour le diagnostic in vitro du cancer du sein

Legal Events

Date Code Title Description
FG Grant or registration